NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name (Descending) | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
64679-0636-02 | 64679-0636 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
62756-0093-40 | 62756-0093 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 7, 2012 | Jan. 31, 2017 | No Longer Used | |
62756-0093-44 | 62756-0093 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug. 31, 2012 | Jan. 31, 2017 | No Longer Used | |
62756-0094-40 | 62756-0094 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 7, 2012 | Nov. 30, 2016 | No Longer Used | |
62756-0094-44 | 62756-0094 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug. 31, 2012 | Nov. 30, 2016 | No Longer Used | |
62756-0095-40 | 62756-0095 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 7, 2012 | Nov. 30, 2016 | No Longer Used | |
62756-0095-44 | 62756-0095 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug. 31, 2012 | Nov. 30, 2016 | No Longer Used | |
00641-6175-01 | 00641-6175 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 4, 2005 | In Use | ||
00641-6175-10 | 00641-6175 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 4, 2005 | In Use | ||
00641-6176-01 | 00641-6176 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 4, 2005 | In Use | ||
00641-6176-10 | 00641-6176 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 4, 2005 | In Use | ||
00781-3164-75 | 00781-3164 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Oct. 21, 1988 | Oct. 31, 2016 | In Use | |
00781-3165-75 | 00781-3165 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Oct. 21, 1988 | Nov. 30, 2016 | In Use | |
00781-3167-71 | 00781-3167 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Feb. 4, 2014 | Feb. 4, 2014 | In Use | |
00781-3167-95 | 00781-3167 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Feb. 4, 2014 | Feb. 4, 2014 | In Use | |
00781-3168-71 | 00781-3168 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Feb. 4, 2014 | Feb. 4, 2014 | In Use | |
00781-3168-95 | 00781-3168 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Feb. 4, 2014 | Feb. 14, 2014 | In Use | |
67457-0239-00 | 67457-0239 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 12, 2013 | In Use | ||
67457-0239-01 | 67457-0239 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 1, 2011 | In Use | ||
76135-0005-01 | 76135-0005 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous | Jan. 1, 2019 | In Use | ||
76135-0006-01 | 76135-0006 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous | Jan. 1, 2019 | In Use | ||
67457-0245-00 | 67457-0245 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 12, 2013 | In Use | ||
67457-0245-01 | 67457-0245 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 1, 2011 | In Use | ||
67457-0246-00 | 67457-0246 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 12, 2013 | In Use | ||
67457-0246-01 | 67457-0246 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 1, 2011 | In Use | ||
25021-0451-01 | 25021-0451 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 15, 2013 | In Use | ||
25021-0452-01 | 25021-0452 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 15, 2013 | Jan. 31, 2023 | In Use | |
25021-0453-01 | 25021-0453 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 15, 2013 | Feb. 28, 2023 | In Use | |
25021-0454-05 | 25021-0454 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 15, 2013 | March 31, 2021 | In Use | |
23155-0685-31 | 23155-0685 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 25, 2022 | In Use | ||
23155-0686-31 | 23155-0686 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 25, 2022 | In Use | ||
00641-6174-01 | 00641-6174 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 4, 2005 | In Use | ||
00641-6174-10 | 00641-6174 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 4, 2005 | In Use | ||
00703-3301-01 | 00703-3301 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Nov. 14, 2005 | In Use | ||
00703-3301-04 | 00703-3301 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Nov. 14, 2005 | In Use | ||
00703-3311-01 | 00703-3311 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Nov. 14, 2005 | In Use | ||
00703-3311-04 | 00703-3311 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Nov. 14, 2005 | In Use | ||
00703-3321-01 | 00703-3321 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Nov. 14, 2005 | In Use | ||
00703-3321-04 | 00703-3321 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Nov. 14, 2005 | In Use | ||
00703-3321-91 | 00703-3321 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Jan. 28, 2008 | Oct. 31, 2011 | In Use | |
00703-3333-01 | 00703-3333 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Nov. 23, 2005 | In Use | ||
00703-3321-94 | 00703-3321 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Jan. 28, 2008 | Oct. 31, 2011 | In Use | |
00703-3343-01 | 00703-3343 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Nov. 23, 2005 | In Use | ||
25021-0463-01 | 25021-0463 | Octreotide acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 15, 2023 | In Use | ||
25021-0464-01 | 25021-0464 | Octreotide acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 15, 2023 | In Use | ||
25021-0465-01 | 25021-0465 | Octreotide acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 15, 2023 | In Use | ||
25021-0466-05 | 25021-0466 | Octreotide acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 15, 2023 | In Use | ||
25021-0467-05 | 25021-0467 | Octreotide acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 15, 2023 | In Use | ||
68462-0896-10 | 68462-0896 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug. 9, 2023 | In Use | ||
68462-0897-10 | 68462-0897 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug. 9, 2023 | In Use | ||
25021-0455-05 | 25021-0455 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 15, 2013 | Feb. 29, 2020 | In Use | |
68083-0515-01 | 68083-0515 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | June 13, 2023 | In Use | ||
68083-0516-01 | 68083-0516 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | June 13, 2023 | In Use | ||
68083-0517-10 | 68083-0517 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | June 22, 2023 | In Use | ||
68083-0560-10 | 68083-0560 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | June 22, 2023 | In Use | ||
63323-0376-01 | 63323-0376 | OCTREOTIDE ACETATE | Octreotide | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | March 14, 2006 | In Use | ||
63323-0376-04 | 63323-0376 | OCTREOTIDE ACETATE | Octreotide | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | March 14, 2006 | In Use | ||
63323-0377-01 | 63323-0377 | OCTREOTIDE ACETATE | Octreotide | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | March 14, 2006 | In Use | ||
63323-0377-04 | 63323-0377 | OCTREOTIDE ACETATE | Octreotide | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | March 14, 2006 | In Use | ||
63323-0378-05 | 63323-0378 | OCTREOTIDE ACETATE | Octreotide | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | March 14, 2006 | In Use | ||
63323-0379-05 | 63323-0379 | OCTREOTIDE ACETATE | Octreotide | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | March 14, 2006 | In Use | ||
63323-0365-01 | 63323-0365 | OCTREOTIDE ACETATE | Octreotide | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | March 14, 2006 | June 30, 2017 | No Longer Used | |
63323-0365-04 | 63323-0365 | OCTREOTIDE ACETATE | Octreotide | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | March 14, 2006 | June 30, 2017 | No Longer Used | |
16729-0332-03 | 16729-0332 | OXALIPLATIN | OXALIPLATIN | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 17, 2018 | In Use | |
16729-0332-05 | 16729-0332 | OXALIPLATIN | OXALIPLATIN | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 17, 2018 | In Use | |
72187-0101-03 | 72187-0101 | Elacestrant | ORSERDU | 86.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan. 27, 2023 | In Use | |
72187-0102-03 | 72187-0102 | Elacestrant | ORSERDU | 345.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan. 27, 2023 | In Use | |
00003-7125-11 | 00003-7125 | nivolumab and relatlimab-rmbw | OPDUALAG | 12.0 mg/mL, 4.0 mg/mL | Immunotherapy | Checkpoint Inhibitor, Monoclonal Antibody | PD-1, LAG3 | Intravenous | March 18, 2022 | In Use | |
00003-3756-14 | 00003-3756 | nivolumab | OPDIVO | 10.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Aug. 30, 2021 | In Use | |
00003-3734-13 | 00003-3734 | Nivolumab | OPDIVO | 10.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Dec. 8, 2017 | In Use | |
59572-0730-07 | 59572-0730 | azacitidine | ONUREG | 200.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec. 18, 2020 | In Use | |
59572-0730-14 | 59572-0730 | azacitidine | ONUREG | 200.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sept. 1, 2020 | In Use | |
59572-0740-07 | 59572-0740 | azacitidine | ONUREG | 300.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec. 18, 2020 | In Use | |
59572-0740-14 | 59572-0740 | azacitidine | ONUREG | 300.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sept. 1, 2020 | In Use | |
64679-0726-01 | 64679-0726 | ondansetron hydrochloride | ONDANSETRON HYDROCHLORIDE | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 27, 2006 | In Use | |
64679-0727-01 | 64679-0727 | ondansetron hydrochloride | ONDANSETRON HYDROCHLORIDE | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 27, 2006 | In Use | |
35356-0679-10 | 35356-0679 | ONDANSETRON HYDROCHLORIDE | ONDANSETRON HYDROCHLORIDE | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 25, 2007 | June 30, 2019 | In Use |
35356-0679-30 | 35356-0679 | ONDANSETRON HYDROCHLORIDE | ONDANSETRON HYDROCHLORIDE | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 25, 2007 | June 30, 2019 | In Use |
51655-0800-04 | 51655-0800 | ONDANSETRON HYDROCHLORIDE | ONDANSETRON HYDROCHLORIDE | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 30, 2014 | In Use | |
67457-0769-02 | 67457-0769 | ONDANSETRON HYDROCHLORIDE | ONDANSETRON HYDROCHLORIDE | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 31, 2017 | In Use | |
51662-1539-01 | 51662-1539 | ONDANSETRON | ONDANSETRON | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct. 6, 2021 | In Use | |
00404-9930-02 | 00404-9930 | ONDANSETRON | ONDANSETRON | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Jan. 13, 2022 | In Use | |
76045-0216-20 | 76045-0216 | ONDANSETRON HYDROCHLORIDE | ONDANSETRON | 4.0 mg/2mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | May 31, 2022 | In Use | |
51662-1246-04 | 51662-1246 | ONDANSETRON | ONDANSETRON | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 19, 2018 | In Use | |
52584-0069-00 | 52584-0069 | ONDANSETRON | ONDANSETRON | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | July 3, 2018 | Nov. 30, 2023 | No Longer Used |
51662-1245-01 | 51662-1245 | ONDANSETRON | ONDANSETRON | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sept. 23, 2018 | In Use | |
51662-1245-03 | 51662-1245 | ONDANSETRON | ONDANSETRON | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sept. 23, 2018 | In Use | |
73441-0800-04 | 73441-0800 | omidubicel-onlv | OMISIRGE | Ancillary Therapy | Immunostimulant | Stem cell mobilizer | Intravenous | May 1, 2023 | In Use | ||
82448-0050-18 | 82448-0050 | Nirogacestat | OGSIVEO | 50.0 mg/1 | Ancillary Therapy | Miscellaneous Agent | Ɣ Secretase Inhibitor | Oral | Nov. 27, 2023 | In Use | |
83257-0001-11 | 83257-0001 | Trastuzumab-dkst | OGIVRI | 150.0 mg/7.4mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct. 1, 2023 | In Use | |
83257-0003-01 | 83257-0003 | Trastuzumab-dkst | OGIVRI | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct. 1, 2023 | In Use | |
83257-0004-12 | 83257-0004 | Trastuzumab-dkst | OGIVRI | Immunotherapy | Monoclonal Antibody | HER2 | Oct. 1, 2023 | In Use | |||
67457-0847-44 | 67457-0847 | Trastuzumab | OGIVRI | 420.0 mg/ 20 mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Nov. 29, 2019 | April 30, 2027 | In Use |
67457-0991-15 | 67457-0991 | Trastuzumab | OGIVRI | 150.0 mg/7.4mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Nov. 29, 2019 | Feb. 28, 2027 | In Use |
76135-0009-01 | 76135-0009 | OCTREOTIDE ACETATE | OCTREOTIDE ACETATE | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Feb. 1, 2019 | In Use | ||
76135-0010-01 | 76135-0010 | OCTREOTIDE ACETATE | OCTREOTIDE ACETATE | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Feb. 1, 2019 | In Use | ||
76135-0011-01 | 76135-0011 | OCTREOTIDE ACETATE | OCTREOTIDE ACETATE | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Feb. 1, 2019 | In Use | ||
23155-0687-41 | 23155-0687 | OCTREOTIDE ACETATE | OCTREOTIDE ACETATE | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Sept. 3, 2019 | In Use | ||
23155-0688-41 | 23155-0688 | OCTREOTIDE ACETATE | OCTREOTIDE ACETATE | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Sept. 3, 2019 | In Use | ||
23155-0689-41 | 23155-0689 | OCTREOTIDE ACETATE | OCTREOTIDE ACETATE | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Sept. 3, 2019 | In Use |
Found 10,000 results in 11 milliseconds — Export these results